Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906035 · ClinicalTrials.gov registry record · NA
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
A NA study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00906035: Clinical Trial NA study, sponsored by University of Pennsylvania.
NCT00906035 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00906035, a NA study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
Interventions
- DRUG Dipyridamole 200mg and Aspirin 25mg bid:
- DRUG Dipyridamole 200 mg bid
- DRUG Aspirin 25 mg bid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-09 |
| Est. Completion | 2010-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00906035
The ClinicalTrials.gov registry entry for NCT00906035 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dipyridamole 200mg and Aspirin 25mg bid: is the first listed.
NCT00906035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00906035 about?
NCT00906035 is a clinical study titled "The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)". This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow ...
What is the current status of trial NCT00906035?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2002-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00906035?
The interventions under investigation include: Dipyridamole 200mg and Aspirin 25mg bid: (DRUG), Dipyridamole 200 mg bid (DRUG), Aspirin 25 mg bid (DRUG).
Who is sponsoring clinical trial NCT00906035?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.